$1.72
(Market cap
$579,826 Mln
Revenue (TTM)
$96,362 Mln
P/E Ratio
27.9
P/B Ratio
7.1
Div. Yield
2.2 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$15,805 Mln
-
ROE
0.3 %
-
ROCE
22.6 %
-
Industry P/E
30.75
-
EV/EBITDA
18.2
-
Debt to Equity
0.5
-
Book Value
$33.7
-
EPS
$8.6
-
Face value
--
-
Shares outstanding
2,407,216,971
10 Years Aggregate
CFO
$214,121.00 Mln
EBITDA
$225,943.00 Mln
Net Profit
$168,674.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
| 16.0 | 8.4 | -1.2 | 54.6 | 14.5 | 7.8 | 7.5 |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Midcap 400
| 13.4 | 2.9 | 11.1 | 24.4 | 14.3 | 6.6 | 9.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
| 43.1 | -7.7 | -11.3 | 3.3 | 8.7 | 7.9 | 13.0 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
|
240.1 | 579,826.4 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 27.9 | 7.1 |
| 227.2 | 397,122.0 | 62,819.0 | 3,639.0 | 14.1 | -- | 109.6 | 50.5 | |
| 354.9 | 188,671.2 | 37,238.0 | 7,800.0 | 29.1 | 82.9 | 24.3 | 20.5 | |
| 1,145.3 | 1,035,267.1 | 72,249.5 | 25,275.0 | 44.1 | 91.9 | 41.3 | 32.5 | |
| 125.5 | 160,361.2 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 17.6 | 6.8 | |
| 120.0 | 298,256.0 | 65,593.0 | 8,935.0 | 24.7 | 18.3 | 34 | 6.4 | |
| 153.5 | 293,693.5 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 22.1 | 7.6 | |
| 26.2 | 149,154.5 | 63,315.0 | 7,491.0 | 16.7 | 8.1 | 20 | 1.6 | |
| 16.0 | 50,144.0 | 4,777,450.3 | 203,326.8 | 13.7 | 2.8 | 42.9 | 1.0 | |
| 34.2 | 40,242.6 | 17,348.0 | 1,564.0 | 13.1 | 20.2 | 25.8 | 4.9 |
Shareholding Pattern
View DetailsAbout Johnson & Johnson (JNJ)
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative... Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey. Read more
-
CEO & Chairman
Mr. Joaquin Duato
-
CEO & Chairman
Mr. Joaquin Duato
-
Headquarters
New Brunswick, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Johnson & Johnson (JNJ)
What is the current share price of Johnson & Johnson (JNJ) Today?
The share price of Johnson & Johnson (JNJ) is $240.05 (NYSE) as of 12-Jun-2026 13:46 EDT. Johnson & Johnson (JNJ) has given a return of 14.48% in the last 3 years.
What is the current PB & PE ratio of Johnson & Johnson (JNJ)?
The P/E ratio of Johnson & Johnson (JNJ) is 27.94 times as on 12-Jun-2026, a 9 discount to its peers’ median range of 30.75 times.
The P/B ratio of Johnson & Johnson (JNJ) is 7.14 times as on 12-Jun-2026, a 29 premium to its peers’ median range of 5.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.83
|
6.19
|
|
2024
|
24.95
|
4.91
|
|
2023
|
10.84
|
5.54
|
|
2022
|
26.23
|
6.13
|
|
2021
|
21.88
|
6.17
|
What is the 52 Week High and Low of Johnson & Johnson (JNJ)?
The 52-week high and low of Johnson & Johnson (JNJ) are Rs 251.71 and Rs 149.04 as of 13-Jun-2026.
What is the market cap of Johnson & Johnson (JNJ)?
Johnson & Johnson (JNJ) has a market capitalisation of $ 579,826 Mln as on 12-Jun-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Johnson & Johnson (JNJ)?
Before investing in Johnson & Johnson (JNJ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.